Liver Fibrosis Treatment Market: Emerging Therapies, Technological Innovations, and Future Growth Opportunities Through 2031 | Novartis AG, Vertex Pharmaceuticals Incorporated

Market Overview:

Liver fibrosis is the formation of scar tissue in the liver caused by chronic inflammation or other liver injuries. It leads to the disruption of the normal liver architecture and function. The main treatments for liver fibrosis include anti-fibrotic drugs and liver transplantation.

Market Dynamics:

The liver fibrosis treatment market is expected to witness high growth during the forecast period owing to the rising prevalence of chronic liver diseases such as non-alcoholic fatty liver disease (NAFLD) and hepatitis. According to the Global Liver Institute, NAFLD is currently the most common chronic liver disease in Western countries, affecting approximately 25% of the world population. Additionally, increasing research activities for developing novel anti-fibrotic drugs and pipeline drugs in late stage clinical trials are also expected to boost the market growth during the forecast period.

Request Sample Copy of the Report at: - https://www.coherentmarketinsights.com/insight/request-sample/2320

List of TOP Players in Market Report are: -

◘ Gilead Sciences Inc.
◘ Merck & Co. Inc.
◘ Bristol-Myers Squibb
◘ Johnson and Johnson
◘ Novartis AG
◘ Vertex Pharmaceuticals Incorporated
◘ Pfizer Inc.
◘ FibroGen Inc.
◘ Pharmaxis Limited

Market Detailed Segmentation:

By Treatment Type: Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist, ACE Inhibitors, Hepatotropic Drug, Others
By Condition: Chronic Liver Diseases, Hepatitis C, Nonalcoholic Steatohepatitis
By Distribution Channel: Hospitals, Specialty Clinics, Others
Growing Prevalence of Liver Diseases Driving Market Growth

The increasing prevalence of chronic liver diseases around the world is driving the growth of the liver fibrosis treatment market. Chronic liver diseases like non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are becoming more common due to rising obesity rates and lifestyle changes. NAFLD is now the most common liver disease in developed countries affecting up to 25% of the population. As these conditions progress to more advanced fibrotic stages, it becomes important to manage liver fibrosis to prevent further progression to cirrhosis or liver failure. This is increasing the demand for anti-fibrotic drugs and other treatment options for liver fibrosis.

Development of Novel Drug Therapies Fueling Growth

The development of novel drug therapies targeting different disease pathways involved in liver fibrosis is boosting the growth prospects of the market. Pharmaceutical companies are investing heavily in R&D to come up with new anti-fibrotic drug formulations. Several drug candidates targeting key mechanisms like inhibition of collagen production, stimulating matrix degradation, inhibiting inflammation and preventing activation of hepatic stellate cells are in clinical trials. For example, candidates like Cenicriviroc, Selonsertib and Elafibranor have shown promising results in Phase 2/3 trials for NASH and fibrosis treatment. The successful approvals and commercialization of these new therapies will drive significant revenue growth in the coming years.

Cost of Treatment Acting as a Market Restrain

The high cost involved in the treatment of liver fibrosis using existing therapies is a major factor restraining the market growth. Many anti-fibrotic drugs in the pipeline are biologics which tend to be very expensive. For example, analysts project Galectin Therapeutics' candidate GR-MD-02 to be priced around $50,000 per year if approved. Similarly, Intercept Pharmaceuticals' obeticholic acid costs over $66,000 per year. The high financial burden on patients limits the wide adoption of these therapies. This hinders the market's revenue potential to a certain extent.

Buy This Premium Report and Get Upto 25 % OFF: https://www.coherentmarketinsights.com/insight/buy-now/2320

Increased Funding for Research Opening New Avenues

The rise in funding for research related to liver fibrosis treatment from government as well as private organizations is creating new opportunities for market players. Large amounts are being invested by public research institutes like the National Institutes of Health (NIH) and private foundations to discover novel targets and develop advanced treatment strategies. For instance, the NIH has invested over $10 million in the Cirrhosis Clinical Research Network for clinical trials related to cirrhosis and portal hypertension management. Increased cash inflow for research facilitates the development of cutting-edge technologies like gene therapies, stem cell therapies and advanced anti-fibrotic agents in the foreseeable future.

Adoption of Combination Therapies - Emerging Trend

The growing trend of evaluating combination therapies for liver fibrosis treatment is an emerging pattern within the industry. Combining anti-fibrotic drugs that work via different mechanisms is being explored to achieve maximum efficacy. Several ongoing studies are evaluating the efficacy and safety of combining existing drugs with novel candidates. For instance, a Phase 2 trial is looking at the impact of combining selonsertib and simtuzumab. Combining anti-fibrotics with other classes of drugs like immunomodulators is also generating interest. This reflects the focus on multi-targeted regimens for improved outcomes compared to single agent therapies. Such combination based products and treatment strategies are likely to dominate the landscape in the long run.

Furthermore, the years considered for the study are as follows:

Historical data - 2016-2022
The base year for estimation - is 2022
Estimated Year - 2024
Forecast period** - 2024 to 2031

This Liver Fibrosis Treatment Market Research/Analysis Report Contains Answers to your following Questions:

◈What are the current global trends in the Liver Fibrosis Treatment market, and will the market experience an increase or decrease in demand in the upcoming years?

◈ What is the expected demand for various product types within the Liver Fibrosis Treatment market, and what are the emerging Market applications and trends?

◈ What are the projections for the global Liver Fibrosis Treatment Market in terms of capacity, production, production value, cost, profit, market share, supply, consumption, import, and export?

◈ How will strategic developments shape the Market trajectory in the medium to long term?

◈ What factors contribute to the final price of Liver Fibrosis Treatment , and what are the raw materials used in its manufacturing?

◈ What is the market's growth potential, particularly with the increasing adoption of Liver Fibrosis Treatment in mining?

◈ What is the current and 2022 value of the global market, and who are the leading companies in this market?

◈ What recent Market trends can be leveraged to create additional revenue streams?

◈ What entry strategies, economic impact mitigation measures, and marketing channels should be considered for the Liver Fibrosis Treatment Market?

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/2320

Summarized Extracts from TOC of Market Study

Chapter 1 Liver Fibrosis Treatment Introduction and Market Overview

1.1 Objectives of the Study

1.2 Overview of Liver Fibrosis Treatment

1.3 Scope of The Study

1.3.1 Key Market Segments

1.3.2 Players Covered

1.3.3 COVID-19's impact on the Liver Fibrosis Treatment industry

1.4 Methodology of The Study

1.5 Research Data Source

Chapter 2 Executive Summary

Chapter 3 Industry Chain Analysis

Chapter 4 Market, by Type

Chapter 5 Market, by Application

Chapter 6 Market Analysis by Regions

Chapter 7 North America Market Analysis by Countries

Chapter 8 Europe Liver Fibrosis Treatment Market Analysis by Countries

Chapter 9 Asia Pacific Liver Fibrosis Treatment Market Analysis by Countries

Chapter 10 Middle East and Africa Liver Fibrosis Treatment Market Analysis by Countries

Chapter 11 South America Liver Fibrosis Treatment Market Analysis by Countries

Chapter 12 Competitive Landscape

Chapter 13 Industry Outlook

Chapter 14 Market Forecast

Chapter 15 New Project Feasibility Analysis

Contact Us

Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame,
CA 94010, United States
Phone: US +12067016702 / UK +4402081334027
JAPAN:+81-50-5539-1737
INDIA:+91-848-285-0837
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.